Leerink Partnrs Increases Earnings Estimates for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for shares of REGENXBIO in a report issued on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($1.25) per share for the year, up from their previous estimate of ($1.87). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2028 earnings at $1.10 EPS.

A number of other research analysts have also weighed in on the stock. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Morgan Stanley restated an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. Raymond James reaffirmed an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright increased their price objective on REGENXBIO from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.64.

REGENXBIO Trading Up 0.7 %

Shares of REGENXBIO stock opened at $9.63 on Thursday. The firm has a fifty day simple moving average of $10.37 and a 200-day simple moving average of $12.14. The stock has a market capitalization of $477.07 million, a price-to-earnings ratio of -1.91 and a beta of 1.23. REGENXBIO has a 1-year low of $8.53 and a 1-year high of $28.80.

Insider Activity

In other news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 13.13% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds have recently made changes to their positions in RGNX. FMR LLC grew its stake in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the last quarter. nVerses Capital LLC increased its holdings in REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 3,720 shares during the last quarter. Diversified Trust Co acquired a new position in REGENXBIO in the second quarter worth $121,000. Finally, Arizona State Retirement System grew its holdings in shares of REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 1,997 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.